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ABSTRACT
Inflammation is a double-edged sword with both detrimental and beneficial 
consequences. Understanding of the mechanisms of crosstalk between the 
inflammatory milieu and human adult mesenchymal stem cells is an important basis 
for clinical efforts. Here, we investigate changes in the transcriptional response of 
human adipose-derived stem cells to physiologically relevant levels of IL-2 (IL-2 
priming) upon replicative senescence. Our data suggest that replicative senescence 
might dramatically impede human mesenchymal stem cell (MSC) function via global 
transcriptional deregulation in response to IL-2. We uncovered a novel senescence-
associated transcriptional signature in human adipose-derived MSCs hADSCs after 
exposure to pro-inflammatory environment: significant enhancement of the expression 
of the genes encoding potent growth factors and cytokines with anti-inflammatory 
and migration-promoting properties, as well as genes encoding angiogenic and anti-
apoptotic promoting factors, all of which could participate in the establishment of 
a unique microenvironment. We observed transcriptional up-regulation of critical 
components of the nitric oxide synthase pathway (iNOS) in hADSCs upon replicative 
senescence suggesting, that senescent stem cells can acquire metastasis-promoting 
properties via stem cell-mediated immunosuppression. Our study highlights 
the importance of age as a factor when designing cell-based or pharmacological 
therapies for older patients and predicts measurable biomarkers characteristic of an 
environment that is conducive to cancer cells invasiveness and metastasis.
INTRODUCTION
Transplanted mesenchymal stem cells (MSCs) 
are consistently exposed to tissue signals, immune cells 
and mediators that could influence their behavior. The 
mechanisms by which this environment influences 
potential therapeutic outcomes in MSC clinical 
applications remain poorly understood, however, over the 
past decade MSCs themselves have been shown to possess 
a broad spectrum of signaling capabilities, affecting both 
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adaptive and innate immunity by the secretion of growth 
factors and chemokines to induce cell proliferation, 
angiogenesis, interactions with the immune system and 
mediation of anti-apoptotic events [1, 2]. Based on these 
remarkable properties, the MSCs are considered to have 
therapeutic potential to treat broad spectrum of diverse 
human diseases, including cancer [3]. 
The most favorable way of using the full potential 
of MSCs as a therapeutic is the clinical utilization of 
autologous (patient specific) or syngeneic (genetically 
similar) cells. To date, little is known regarding the extent 
to which the beneficial properties of MSC change with the 
age of the patient or upon MSCs expansion and passaging 
ex-vivo, where the length of expansion period, culture 
methods and the patient’s clinical history can all lead to 
a gradual accumulation of replicatively senescent cells. 
Replicative senescence is characterized by a growth arrest, 
apoptosis resistance, morphological and cell-size changes, 
high levels of expression of the tumor suppressors P16, 
P21, P53 and/or RB, increased activity of senescence-
associated beta galactosidase (SA-β-gal) and loss of the 
ability to synthesize and repair DNA [4, 5]. Numerous 
reports indicate that the replicative aging of stem cells 
and MSCs, in particular, can influence their biological 
properties, including their ability to secrete beneficial 
factors [6-9].
The primary trophic property of MSCs is secretion 
of mitogenic growth factors such as transforming growth 
factor-alpha (TGF-α), TGF-β, hepatocyte growth factor 
(HGF), epithelial growth factor (EGF), basic fibroblast 
growth factor (FGF-2), vascular endothelial growth factor 
(VEGF) and insulin-like growth factor-1 (IGF-1). All of 
these factors, when present in the systemic milieu, have 
shown to increase fibroblasts along with epithelial and 
endothelial cell division or differentiation [3, 10-13]. 
This provides evidence that the MSC-triggered cellular 
communication circuitry is necessary for tissue or organ 
remodeling and regeneration. Interestingly, the secretion 
of a wide array of growth factor and anti-inflammatory 
proteins by MSCs could also be modulated in response 
to inflammatory molecules, such as interlukin-1 (IL-
1), IL-2, IL-12, tumor necrosis factor-alpha (TNF-α) 
and interferon-gamma (INF-γ) (see for review [3]), 
thereby providing complex signaling guidance to many 
inflammatory cells, including T-cells, natural killer 
cell, B-cells, monocytes, macrophages and endritic 
cells [3, 14-17]. Previous reports have demonstrated 
that pro-inflammatory cytokines were able to increase 
the migration of human MSCs as well as to induce the 
production of chemokines and chemotactic factors that 
permit MSCs to suppress immune reactions [18-20]. The 
best documented immune-modulatory effect of MSCs is 
their ability to impose G0/G1 phase arrest in the activated 
T-cells, thus inhibiting T-cell proliferation [19, 20] [21, 
22]. Despite the notion that the secretion by MSCs of a 
number of the soluble factors (IL-6, IL-10, indoleamine, 
2,3-dioxygenase, iNOS and PGE2) could assist injury 
through the modulation of the regenerative environment 
via anti-inflammatory and immunomodulatory pathways, 
the exact molecular mechanism by which this modulation 
takes place is only partially understood and seemingly 
contradictive, in part due to lack of data that clearly 
articulates how adult stem cell aging in-vivo or ex-vivo 
contributes to immunomodulatory properties. 
This study was conducted to evaluate the impact of 
replicative senescence on the transcriptional activity of 
human adipose-derived MSCs (hADSCs) in response to 
IL-2 signaling. Our results uncovered significant changes 
imposed by replicative senescence on biological pathways 
related to stem cell response to IL-2 priming, and suggest 
that such changes might dramatically influence outcomes 
of clinical application of hADSCs by affecting their 
immunomodulatory and migration properties as well as 
their ability to influence the regenerative environment.
RESULTS
Characterization of the MSC senescent phenotype
Mesenchymal stem cells (MSCs) are mesoderm-
derived cells that reside in the stroma of solid organs and 
function as precursors of non-hematopoietic connective 
tissues with the capacity to differentiate into mesenchymal 
and non-mesenchymal cell lineages. Adipose-derived 
MSCs (ADSCs) are more accessible, compared to bone 
marrow BM-MSCs, more abundant, and equally capable of 
differentiating into cells and tissues of mesodermal origin 
[23]. ADSCs also share some of the immunomodulatory 
properties that characterize BM-MSCs. Reported data 
indicate that ADSCs could effectively down-regulate 
excessive immunologic reactions and have a protective 
effect on acute graft-versus-host disease, as well as in 
animal models of experimental arthritis [24, 25]. hADSCs 
were isolated and cultured as described in the Materials 
and Methods and in [7]. Ex-vivo replicative senescence 
led to decreased proliferation, accumulation of DNA 
damage and observed typical morphological changes: 
hADSCs became much larger with irregular and flat shape, 
and nuclei became more circumscribed in phase contrast 
microscopy with the granular cytoplasm appearance of 
many inclusions and aggradations [6, 7]. The growth 
curves of hADSCs obtained from two different patients 
are shown in Figure 1A. Typical staining for senescence-
associated SA-β galactosidase activity for either hADSCs 
in linear growth rate, self-renewing state (SR) or when 
cell lines cease their proliferation, senescent state (SEN) is 
shown in Figure 1B and described in detail in [7]. 
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Table 1: Biological pathways enriched for genes up-regulated upon IL-2 treatment in self-replicating (SR) and/or 
senescent (SEN) hADSCs.
Enriched pathways are shown along with the individual IL-2+ up-regulated genes belonging to the pathway and the pathway enrichment 
significance levels. Pathways with gene members up-regulated in SR are shown in the left column, and pathways with gene members up-
regulated in SEN are shown in the right column. Pathways with gene members up-regulated in both SR and SEN are shown in the top row 
followed by pathways with gene members up-regulated only in SEN, and finally pathways with gene members up-regulated only in SR. 
Networks are shown relating pathways that are up-regulated in SR (left column) and pathways that are up-regulated in SEN (right column). 
The network nodes represent pathways, and the sizes of the nodes correspond to the number of up-regulated genes in that pathway. Pathway 
nodes are connected by edges if the pathways share up-regulated genes, and edge-weights correspond to the number of up-regulated genes 
shared between the pathways.
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Replicative senescence ADSCs demonstrate a 
higher propensity for migration
One of the important characteristics of MSCs 
is their ability to migrate to sites of damaged tissue 
[26]. To investigate whether or not ex-vivo replicative 
senescence affects the migratory potential of hADSCs, we 
have performed migration assays with a set of common 
cytokines and relevant growth factors using the Transwell 
system as described in the Materials and Methods. We 
observed that SEN hADSCs showed significantly higher 
basal migration capacity than their SR counterparts (Figure 
1C). In addition, the response of SEN hADSCs to different 
cytokine chemo-attractants was measured. The factors IL-
2, IL-6, IL-8 as well as TNF-α and HMGB1 have been 
Figure 1: Replicative senescence impairs migratory properties of the hADSCs. A. Growth curve of the hADSCs is represented 
as cumulative population doubling over day in culture. Two patient-specific cell lines were used for the study (Female, 32 years old, 
*-Female 45 years old ). Linear proliferation stage for both lines shown in blue (SR) and stages when hADSC enter senescence shown in 
red (SEN) B. Colometric detection of senescence-associated β-galactosidase (10x) in self-renewing (SR) and senescent (SEN) hADSCs . C. 
Ex-vivo migration assays for self-renewing (SR-blue) and senescent (SEN-red) hADSCs were performed in complete DMEM-F12 media. 
The black lines indicate the median values, and the whiskers indicate the range of values. Statistical difference was evaluated by t- test with 
P-value (p) as depicted. D. Self-renewing SR (blue) and senescence SEN (red) hADSCs were induced to migrate in the presence of different 
cytokines (50 ng/ml IL-2, IL-6, IL-8, HMGB1; 30 ng/ml TNF). The graphic represents the mean of ten independent experiments (n = 10). 
P-values (p) related to experimental measurements are listed under the graphs.
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previously reported as potent chemo-attractants inducing 
migration of different stem cell types [27, 28]. Our data 
indicate that hADSCs at late passages have an increased 
ability to migrate in comparison to early passages (Figure 
1D), indicating that replicative senescence increases 
the migratory properties of hADSCs in response to the 
tested chemo-attractants. Interestingly, upon senescence 
of hADSCs interleukin-2 (IL-2) became the most potent 
chemo-taxis stimulant whereas the TNF-α is less potent 
among the tested chemo-attractants in these experiments 
(Figure 1D). 
Collectively, these data indicate that replicative 
senescence can modify the migratory properties of 
hADSCs and may possibly influence hADSCs response 
to the inflammatory environment as well as their 
immunomodulation output ex-vivo.
Differential response to IL-2 stimulation in 
human adipose-derived MSCs upon replicative 
senescence
IL-2 is a ligand used by cells expressing either the 
intermediate-affinity receptor dimer of IL2Rβ (CD122) 
and the common IL2Rγ (CD132), or the high-affinity 
trimeric IL2R comprising IL2Rα (CD25) in addition to 
the IL2Rβ and IL2Rγ isoforms (shown in Figure 2A). 
The intermediate-affinity IL-2 receptor is more broadly 
expressed on T-cells, natural killer cells and monocytes 
[29]. The high-affinity IL-2 receptor is constitutively 
expressed on regulatory T-cells (Treg). Information about 
the role of IL-2 signaling in non-T-cells is limited, but 
nevertheless suggests the existence of similar stimulatory 
receptor representations in other cell types [30-32]. 
Currently, it is unknown how hADSCs are affected by 
therapeutic doses of IL-2, and whether or not there are 
changes that occur in IL-2 receptor composition or IL-2 
receptor signaling upon ex-vivo replicative senescence of 
this type of human MSCs.
Assessment of the IL-2 receptor isoforms expression 
by qPCR demonstrated dramatic changes in expression of 
the IL2Rα isoform in comparison to IL2Rγ and IL2Rβ upon 
replicative senescence ex-vivo (Figure 2B). Notably, the 
increased accumulation of the IL2Rβ and IL2Rγ transcripts 
was recorded after IL-2 treatment in both SR and SEN 
hADSCs, whereas IL2Rα expression was severely 
abrogated when senescent cells were subjected to similar 
treatments (Figure 2B). However, our data indicate that on 
the protein level, the cellular membrane-associated IL2Rα 
receptor shows the opposite pattern (Figure 2C). Although 
the transcriptional status of IL-2 receptor isoforms does 
vary between the two different cell states (SR and SEN), 
it does not seem to be dependent upon IL-2 priming as 
measured by the ELISA assay (described in the Materials 
and Methods). Interestingly, our data also demonstrate 
that protein encoding IL-2 receptor α chain is far less 
abundant than the IL2Rβ isoform (compare 120 pg/ml of 
IL2Rα and 350 pg/ml IL2Rβ to 150 pg/ml of IL2Rα and 
440 pg/ml IL2Rβ upon replicative senescence ex-vivo) 
as shown in Figure 2C. These data suggest that hADSCs 
response to IL-2 stimulation occurs, by and large, through 
the intermediate-affinity receptor dimer composed of 
IL2Rβ (CD122) and the common IL2Rγ (CD132). These 
data also caution against over-interpretation of receptor-
signaling pathway dynamics based on transcriptional 
assays only.
IL-2 signals via JAK1 and JAK3 to activate 
STAT5A and STAT5B, and additionally uses Ras-MAP 
kinase and phosphoinositol 3-kinase dependent signaling 
pathways (Figure 2A) [33, 34]. The expression of 
downstream target of IL-2, STAT5, is shown in Figure 
3A and 3B and Supplementary Table 1. In hADSCs, both 
STAT5A and STAT5B gene transcription follows the IL-2/
STAT5 signaling axis previously described for T-cells (for 
review see [35]), thus prompting us to investigate in detail 
how IL-2 and its downstream target STAT5 may effect 
transcriptional outcomes in hADSCs upon their replicative 
senescence ex-vivo.
Priming with IL-2 results in altered gene 
expression in human ADSCs upon replicative 
senescence
To address how the transcriptional response to 
the IL-2/STAT5 axis changes upon replicative aging of 
hADSCs ex-vivo, we performed RNA-seq transcriptome 
analysis using the Ion ProtonTM System as described in the 
Material and Methods and shown in Supplementary Figure 
1A. We compared gene expression levels in hADSCs 
across four conditions (libraries): self-renewal upon 
normal ex-vivo culture (SR IL-2–), self-renewal upon 24 
hrs recombinant IL-2 stimulation (SR IL-2+), replicative 
senescence upon normal ex-vivo culture (SEN IL-2–), 
and replicative senescence upon 24 hrs recombinant IL-2 
stimulation (SEN IL-2+). Distributions of the total read 
counts for the four libraries representing each condition 
are shown in Supplementary Figure 1B and 1C.
We used beta-actin expression levels to normalize 
gene expression levels between conditions (see Materials 
and Methods). This approach was taken to allow for the 
fact that overall gene expression levels are likely to change 
upon IL-2 treatment, and using a global normalization 
method to bring the overall expression distributions 
for each condition into register would remove this 
biological signal. Indeed, beta-actin normalized gene 
expression distributions reveal overall up-regulation of 
gene expression upon IL-2 treatment in both SR and SEN 
states (Supplementary Figure 1D). However, comparison 
of individual gene expression levels among the four 
conditions suggests that IL-2 treatment more dramatically 
affects senescent (SEN) compared to self-renewing 
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Figure 2: Gene expression of IL-2 receptor isoforms and their association with membrane in self-renewing (SR) and 
senescent (SEN) hADSCs primed with IL-2. A. Three classes of IL-2 receptors (high-affinity, intermediate affinity, and low affinity), 
with receptor composition and associated JAK kinases are shown as cartoon. Trans-presentation of IL-2Rα expressed by MSCs to immune 
cells that expresses IL-2Rβ and IL-2Rγ has been depicted separately. The soluble IL-2 receptor (soluble sIL-2Rα) with bound IL-2 is not 
shown in the figure. B. IL-2 receptors α, β, γ assessed by quantitative PCR in un-stimulated (IL-2-) senescent (red) and self-renewing 
(blue) hADSCs and upon stimulation with 20ug/ml of recombinant IL-2 (IL-2+). Data shown as fold change ΔΔCT Mean +SD from three 
independent experiments is show. Position of the q-PCR primers off line are depicted graphically C. Cellular membrane associated levels 
of IL-2Rα and IL-2Rβ were quantified by ELISA in un-stimulated (IL-2-) senescent (SEN-red) and self-renewing (SR-blue) hADSCs and 
upon stimulation with 20ug/ml of recombinant IL-2( IL-2+). Data are expressed as picogram per milliliter. Results are the mean of three 
independent experiments (mean ± SD). Statistical significance was estimated by  t- test, where ***p < 0.001, **p < 0.01, *p < 0.05.
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Table 2: Biological pathways enriched for genes down-regulated upon IL-2 treatment in self-replicative (SR) and/or 
senescent (SEN) hADSCs. 
Enriched pathways are shown along with the individual IL-2+ down-regulated genes belonging to the pathway and the pathway enrichment 
significance levels. Pathways with gene members down-regulated in SR are shown in the left column, and pathways with gene members 
down-regulated in SEN are shown in the right column. Pathways with gene members down-regulated in both SR and SEN are shown in the 
top row followed by pathways with gene members down-regulated only in SEN, and finally pathways with gene members down-regulated 
only in SR. A network is shown relating pathways that are down-regulated in SEN (left column). The network nodes represent pathways, 
and the sizes of the nodes correspond to the number of SEN down-regulated genes in that pathway. Pathway nodes are connected by edges 
if the pathways share SEN down-regulated genes, and edge-weights correspond to the number of down-regulated genes shared between 
the pathways.
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(SR) hADSCs (Figure 4A). The SR IL-2– and SR IL-2+ 
conditions group closely together when individual gene 
expression levels are compared followed by the SEN IL-
2– condition. The SEN IL-2+ condition is a clear outlier 
amongst the four conditions showing a substantially 
divergent pattern of individual gene expression levels. This 
suggests the possibility that the biological response to IL-2 
treatment in hADSCs upon senescence might dramatically 
impede MSC function via global transcriptional de-
regulation in response to IL-2. 
Expression levels were further compared between 
conditions in order to identify individual genes that are 
differentially expressed, up- and down-regulated, in 
response to IL-2 treatment in both SR and SEN states 
(Figure 4B). There are far more genes that are up-
regulated (8,866) compared to down-regulated (2,296) 
upon IL-2 treatment in both SR and SEN hADSCs. There 
is also a substantially higher proportion of genes that 
are up-regulated in both SR and SEN hADSCs (35%) 
compared to genes that are down-regulated in both states 
(4%). The greatest asymmetry is seen for genes that are 
down regulated in SEN hADSCs upon IL-2 treatment 
(1,739); there are many more such genes than seen for 
the SR IL-2+ condition (649). This difference suggests 
that the overall divergence of the SEN IL-2+ condition is 
largely attributed to genes that are down-regulated upon 
IL-2 treatment, which is an unexpected result given the 
overall up-regulation across both SR and SEN upon IL-2 
treatment (Figure 4B, 4C, 4D and Supplementary Figure 
1D). 
Taken together, these data suggest the possibility 
that SEN hADSCs have lost the ability to generate a 
response to IL-2 treatment to the same extent as actively 
proliferating cells. The greater number of up-regulated 
genes seen for SR IL-2+, compared to SEN IL-2+, is 
consistent with this interpretation.
Trophic properties of the hADSCs after 
interleukin-2 priming are susceptible to 
replicative aging ex-vivo
The secretion of a broad range of bioactive 
molecules is now believed to be the main mechanism 
by which MSCs achieve their therapeutic effects. MSCs 
secrete an array of growth factors and anti-inflammatory 
proteins with complex feedback mechanisms among 
the many types of immune cells [3]. Our data indicate 
that the expression of growth factors in hADSCs upon 
stimulation with IL-2 is subjected to dramatic changes 
upon replicative senescence ex-vivo. While the priming 
of actively proliferating (SR) hADSCs with IL-2 results 
in increased expression of mitogenic proteins such 
as stromal cell-derived factor-2 (SDF2) and SDFL2, 
and prostaglandin E synthetase-2 (PTGES2), both SR 
and SEN ADSCs are marked by drastic increases of 
Figure 3: Stimulation of the self-renewing and 
senescent hADSCs with IL-2 upregulates mRNA of 
a mediator of IL-2 signaling STAT5 gene. STAT5A and 
STAT5B mRNA expression was assessed by quantitative RT-PCR 
in un-stimulated (IL-2-) senescent (red) and self-renewing (blue) 
hADSCs and upon stimulation with 20ug/ml of recombinant 
IL-2 (IL-2+). Data shown as fold change ΔΔCT Mean ±  SD 
from three independent experiments is shown. Position of the 
qPCR primers are depicted graphically. Statistical significance 
was estimated by  t- test, where ***p < 0.001, **p < 0.01. 
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transforming growth factors alpha and beta (TGFα, 
TGFβ1 and TGFβ2), transforming growth factor beta 
receptor TGFBR2 and transforming growth factor 
beta receptor-associated protein TGFBRAP1, as well 
as transforming growth factor beta-induced (TGFBI), 
which are known to increase fibroblast, epithelial and 
endothelial cell division when secreted in systemic milieu 
(Figure 5A and Table S1 ) [3, 36]. In addition, both SR 
and SEN IL-2 stimulated hADSCs are marked by up-
regulation of colony stimulating factor-1 (CSF-1), LIF, 
IL-11, IL-17D, IL-1β and tumor necrosis factor (ligand) 
superfamily TNFSF13B, a cytokine encoding gene that 
stimulates B- and T-cell function (Figure 5A, 5B and 
Supplementary Table1). Taking into account that paracrine 
IL-17D induces expression of IL-6, IL-8, and GM-CSF 
genes in endothelial cells, and IL-1β stimulates fibroblast 
growth factor activity (TGFα, TGFβ1 and TGFβ2 genes 
are notably up-regulated in IL-2-primed hADSCs) in 
autocrine and paracrine fashion, along with thymocyte 
and B-cell proliferation and maturation by inducing 
release of IL-2 from these cells, our data suggest that the 
transcriptional status of both SR and SEN hADSCs may 
point to enhanced immunomodulatory properties of these 
cells after IL-2 priming via a complex regulatory feed-
back loop.
In addition, we also noted essential differences in 
the IL-2 dependent expression of growth factors upon 
senescence of hADSCs that have not been observed in 
SR cells. This includes up-regulation of only a subset of 
fibroblast growth factor family members (FGF1, FGF11, 
FGF14) accompanied by down-regulation of other 
members, such as FGF2, FGF5, FGF7, (Figure 5A and 
Supplementary Table1). Surprisingly, IL-2 primed SEN 
hADSCs are marked by EGF mRNA up-regulation, but 
down-regulation of mRNA to its receptor EGFR, together 
with decrease in expression of the serum response factor 
SRF and the secreted modulator of WNT signaling 
SFRP1. Interestingly, the expression of both a potent 
mitogen for cells of mesenchymal origin that promotes 
wound healing, PDGFA, and its receptor, PDGFRA, is 
drastically suppressed in SEN hADSCs in comparison to 
SR cells subjected to IL-2 priming (Figure 5A, Table 1 and 
Supplementary Table 1). 
These data revealed essential senescence-related 
differences in the nature of IL-2 mediated transcriptional 
response in hADSCs that might impede their 
immunomodulatory properties ex-vivo and, ultimately, in-
vivo.
Anti-inflammatory and immunomodulatory 
properties of IL-2 primed human MSC
Next, we investigated how exposure to the IL-2 
pro-inflammatory environment, when imposed on 
replicative aging, affects the expression of the genes 
assigned to provide immunomodulatory properties 
of hADSCs. Published data indicated that MSCs can 
prevent proliferation and promote differentiation of 
many inflammatory immune cells, including T-cells, 
natural killer cells, B-cells, monocytes, macrophages and 
dendritic cells through the secretion of paracrine factors 
in response to inflammatory environment [20]. Our data 
demonstrate that this capacity for immunomodulation 
could be severely affected by replicative aging of the 
human adipose-derived MCS during ex-vivo passaging 
(Figure 5B) and Supplementary Table 1. 
IL-2 priming in SEN hADSCs activates distinct 
set of genes attributed to T-cell regulation. IL-2 priming 
of self-renewing hADSCs results in up-regulation 
of genes, such as TNFRSF21 (involved in T-cells 
differentiation), IL12A (T-cell activator), ILF2 (potent 
regulator of transcription of the IL-2 gene during T-cell 
activation), IL33 (paracrine inducer of T-helper type 2 
associated cytokines) and down-regulation of CCL28 
(chemotactic factor for CD4+, CD8+ T-cells), CD320 
(receptor molecule with autocrine and paracrine function 
to augment the proliferation of plasma cells) shown in 
Figure 5B and Supplementary Table 1. Contrary to that, 
IL-2 primed senescent hADSCs are characterized by 
drastic transcriptional up-regulation of CD320, a number 
of integrins which could be involved in modulation 
of T-cell function (ITG11, ITGAV, ITFG1), and genes 
encoding important regulatory molecules such as: the 
T-cell adhesion receptor (CD99), a factor attributed to the 
maintenance of naïve T-cells (CHST3), T-cell activators 
(HIVEP1 and HIVEP2), a gene involved in T-cell 
signaling pathway (CMIP) and an autocrine/paracrine 
factor, PTGER1, involved in inhibition of CD+ cell 
proliferation (Figure 5B and Supplementary Table1). Our 
data also demonstrate that SR hADSCs exposed to IL-2 
trigger down-regulation of transcriptional activities of the 
genes encoding surface receptors that play a role in B-cell 
proliferation and differentiation (CD72) and homing 
macrophages (CD68). Both of these genes are significantly 
transcriptionally up-regulated in senescent cells upon 
similar treatment (Figure 5B and Supplementary Table 1). 
In addition, IL-2 treated SEN hADSCs are set 
apart from similarly treated SR cells by transcriptional 
down-regulation of the genes required for pro-B to 
pre-B transitioning, the LRRC8A and PEAR1 genes, that 
regulate a number of non-adherent myeloid progenitors. In 
contrast, the genes involved in lymphocyte activation and 
homeostasis (CD83 and TNFRSF25) as well as leukocyte 
transmigration (CERCAM), and the genes responsible 
for endothelial cell-leukocyte interaction (ESM1), and a 
gene important for the control of monocytes/macrophage 
mediated immunological process (TNFSF13), are up-
regulated in SEN hADSCs (Figure 5B and Supplementary 
Table 1). 
These observations, together with IL-2 dependent 
differential transcriptional expression of cytokines in 
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Figure 4: Comparison of gene expression levels between self-renewing and senescence hADSCs upon IL-2 treatment. 
A. Hierarchical clustering showing the pairwise distance between conditions based on comparison of condition-specific gene expression 
profiles. B. Venn diagram showing the numbers of genes, which are up-regulated and down-regulated upon IL-2 treatment. C. & D. 
Heatmap showing the expression levels of genes that are up-regulated C. and down-regulated D. upon IL-2 treatment. Normalized gene 
expression levels are color coded as shown in the legend (red = high & green = low). Groups correspond to genes that are up- or down-
regulated in SR-only, SEN-only or both conditions. 
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SEN hADSCs (up-regulation of IL-32, IL-6, PLAU 
genes; down-regulation of CCL2, CLEC11A, ILF3, 
IRAK3, KIF14, MYL9 genes) and in SR hADSCs (up-
regulation of IL12A, IL7R, IRAK1, NOS3 genes; down-
regulation of IL16, CSF1R genes), indicate that the 
putative immunomodulatory properties of hADSCs are 
susceptible to senescence imposed changes and suggest 
novel biological pathways and gene targets that can be 
further explored ex-vivo and in-vivo.
Anti-apoptotic and metastasis promoting 
properties of IL-2-primed hADSCs upon 
replicative senescence
Another important clinical property of MSCs is the 
ability to rescue apoptotic cell death induced by traumatic 
exposures to hypoxia, chemicals/acidity, mechanical 
damage and radiation. For example, MSCs have been 
proven to assist reversal of apoptosis in cardiomyoblasts 
after ischemia, as well as damaged neurons and lung 
fibroblasts [37,38]. Recently, stanniocalcin-1 (STC1) was 
identified as an essential factor capable of potent apoptotic 
reversal in fibroblasts damaged by UV and acidity [39]. 
Our data indicate that IL-2 priming transcriptionally 
upregulates both STC1 and STC2 genes, and such 
activation is not dependent on the replicative aging of 
hADSCs, at least ex-vivo (Supplementary Table1). In 
addition, paracrine effectors such as VEGF and TGFβ1 
have been implicated in the reversal of apoptosis in 
endothelial cells [40]. The expression of genes encoding 
both of these factors is up-regulated in SR and SEN 
hADSCs upon IL-2 treatment (Figure 5C, Figure 6 and 
Supplementary Table 1). However, transcriptional activity 
of VEGFA is notably higher in senescence then in actively 
proliferating cells as further verified by qPCR analysis 
shown in Figure 6. Notably, the SIVA1 gene encoding a 
pro-apoptotic factor and a potent inducer of T-lymphocytes 
apoptosis [41] is significantly down-regulated in senescent 
cells upon IL-2 treatment in comparison to proliferating 
hADSCs (Figure 5C and Supplementary Table1). In 
addition, recently published data indicate that SIVA1 is not 
a strictly pro-apoptotic factor, but also a potent suppressor 
of tumor metastasis [42]. Importantly, a number of the 
factors responsible for invasive growth and metastasis are 
significantly up-regulated in SEN hADSCs primed with 
IL-2 in comparison with similarly treated SR cells (Figure 
5C). This includes PLEKHA1, PLEKHA6, CTSB, CRMP1, 
FERMT1 genes.
These data indicate that pre-treatment/priming 
of hADSCs with IL-2 may enhance the anti-apoptotic 
properties of these cells in general, and such enhancement 
is effected by replicative senescence, at least in culture. On 
the other hand, it should be noted that down-regulation of 
specific genes, such as SIVA1 (and probably many others) 
and up-regulation of genes encoding potent metastasis-
associated factors in SEN hADSCs, is indicative of a 
troublesome phenomenon: IL-2 priming of senescent cells 
or exposure of the senescent cells to a pro-inflammatory 
environment might be critical in shifting the balance 
from immunomodulation to an environment promoting 
metastatic transformation and invasive growth.
Transcriptional profiling suggests gene targets 
regulating enhanced migration and angiogenesis 
in IL-2 stimulated hADSCs upon replicative 
senescence
Further analysis of the transcriptional response 
indicates that IL-2 stimulation of senescent hADSCs 
profoundly enhances the expression of genes involved 
in vascular development and remodeling related to 
angiogenesis. We observed drastic up-regulation of 
the VEGFA, VEGFB, FBLN5, FBLN7, PGF, ANGPT1, 
ANGPT2, ANGPTL2, ANGPTL6, TNFSF12, PRKCA, 
PIK3CA, HRAS genes as well as a gene encoding a 
potent modulator of endothelial cell-leukocyte adhesion, 
ESM1 (Figure 5D, Table 1 and Supplementary Table 1). 
The vascular endothelial growth factor, VEGF, released 
by MCSs enables recruitment of endothelial lineage 
cells and initiation of vascularization as was previously 
reported [43]. We have further demonstrated that up-
regulation of VEGFA gene expression in SEN hADSCs 
can be detected by quantitative RT-PCR analysis and 
IL-2 priming results in a statistically significant increase 
of VEGFA gene transcription in SR and SEN hADSCs 
(Figure 6). Interestingly, we further observed that in 
response to IL-2 priming, a group of genes responsible 
for cell motility, migration and invasive growth are 
drastically up-regulated only in the hADSCs undergoing 
replicative senescence: CGNL1, CGREF1, CRMP1, 
FGD6, TNK2, PTGS1, TNFAIP8, CTSB, CTSO, FAP, 
FERMT1, PLEKHA1, PLEKHA6, ROCK1, ROCK2. In 
concert with this observation, our data indicate that a 
set of genes promoting cell adhesion, such as CHD24, 
CYR61, ILK, NEDD9, MYL9, PPAP2B, RELN and TLN2 
are down-regulated (Figure 5D and Supplementary Table 
1). These data further support the experimental evidence 
for the enhanced migration capacity of senescent hADSCs 
shown in Figure 1C and Figure 1D. 
Equally important, IL-2 priming results in the 
differential expression of a number of cytokines and 
factors critical for chemotaxis (shown in Figure 5B). For 
instance, SR hADSCs are marked by up-regulation of 
IL-33, IL-12A, IL10RB, IL1RAP, IL7R, ILF2 and NOS3 
genes, while IL-16 and CSF1R genes are down-regulated 
in these cells. In SEN hADSCs treated under similar 
conditions with IL-2, the genes encoding cytokines IL-32, 
IL-6, IL1RN, IL20RB, IL21R and inducers of inflammation 
TNFSF13 and TNFSF12, as well as the gene encoding 
extracellular matrix remodeler PLAU are up-regulated 
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Figure 5: Gene expression levels for self-renewing and senescence hADSCs upon IL-2 treatment among functionally 
coherent sets of genes. Expression levels are shown for sets of genes characterized as A- trophic factors, B- anti-inflammatory and 
immunomodulatory, C- anti-apoptotic and metastasis promoting, and D. migration and angiogenesis promoting. Normalized gene 
expression levels are color coded as shown in the legend (red = high & green = low).
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(Table 1 and Supplementary Table 1). At the same time, 
several factors that are essential for cytokinesis such 
as MYL9, KIF14, IRAC3, as well as the gene encoding 
chemotactic factor that attracts monocytes and basophils 
(CCL2) and the CLEC11A gene regulating proliferation 
and differentiation of hematopoietic precursor cells, are 
down-regulated (Figure 5B). Similar down-regulation is 
also found for several interleukin receptor encoding genes 
IL7R, IL1R1, IL15RA, and interleukin enhancer binding 
factors ILF2 and ILF3. Interestingly, TNFSF13(APRIL), a 
novel death-inducing secreted ligand, has been previously 
reported as both a cell proliferation-inducing [44] and cell 
death triggering ligand [45], thus cautioning that the role 
of the individual factors should be further investigated in 
a context-dependent manner.
All together, these data support the hypothesis 
that senescent mesenchymal stem cells, when subjected 
to inflammatory environment, might have decreased 
retention at the delivery site due to increased mobility. 
These same senescent cells may also play a role in tumor 
progression by promoting angiogenesis and metastasis. 
Our data also point to numerous biological targets 
critical for these events that can be prioritized for further 
experimental studies with in-vivo models and in clinical 
settings.
DISCUSSION
hADSCs are currently one of the primary sources 
of stem cells with direct clinical relevance [46]. Human 
MSCs may be able to both sense and respond to their 
immediate environment, which make these cells ideal to 
tune the response to injury and/or inflammation. It has 
been rightfully suggested that MSCs should be called 
Medicinal Signaling Cells as it was suggested in [47, 48]. 
The emerging evidence from studies of autoimmune 
disorders and models of tumorigenesis indicates that the 
immunomodulatory properties of adult mesenchymal 
stem cells can be susceptible to the presence of IL-2 in 
an inflammatory environment [49]. In addition, MSCs 
themselves can produce therapeutic cytokines, such 
as IFN-β [50] and interleukin-2 [51, 52] to provide for 
beneficial anti-tumor effects. IL-2 is a potent cytokine that 
is also proven to boost the immune system to fight cancer. 
There are several FDA approved therapies currently on the 
market that make use of IL-2 to fight metastatic melanoma 
and renal cell carcinoma [53]. However, intravenous 
administration of IL-2 may have an impact on numerous 
tissues and organs in the body, including MSCs. Indeed, 
recent data indicate that MSCs in general, and MSCs 
derived from the adipose tissue, in particular, possess an 
Figure 6: Interleukin-2 upregulates transcription of the VEGFA gene upon replicative senescence of hADSCs. VEFGA 
gene expression was assessed by quantitative qPCR in unstimulated (IL-2-) senescent (red) and self-renewing (blue) hADSCs and upon 
stimulation with 20ug/ml of recombinant IL-2 ( IL-2+). Data shown as fold change ΔΔCT Mean ± SD from three independent experiments 
is show. The position of the q-PCR primers are depicted graphically. Statistical significance was estimated by t - test, where ***p < 0.001, 
**p < 0.01. 
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intrinsic preferential property to migrate actively toward 
some tumor types upon their systemic administration [54-
56]. What remains unclear is how adult mesenchymal stem 
cells may be affected by therapeutic doses of IL-2 and 
what, if any, changes in transcriptional outcomes occur 
with aging in response to IL-2 signaling. Our genome-
wide transcriptomic analysis of hADSCS subjected to IL-2 
exposure/priming ex-vivo demonstrates that senescence 
of stem cells substantially effects their transcriptional 
response.
IL-2 signals via specific receptors, with three classes 
of cell surface receptors formed by various combinations 
of three IL-2R subunits: IL2Rα (CD25), IL2Rβ (CD122) 
and IL2Rγ (CD132) [57]. Our experimental results 
indicate that hADSCs transcriptionally express all three 
receptors, however protein expression of the IL2Rα 
in hADSCs is far lower than seen for IL2Rβ. These 
observations suggest that an IL-2 receptor composition 
consisting of IL2Rβ and IL2Rγ isoforms might mediate 
the predominant form of IL-2 cytokine recognition 
by hADSCs. The receptor composition changes only 
slightly upon replicative aging of the hADSCs (Figure 2), 
indicating that responsiveness of hADSCs to IL-2 does 
not change upon their senescence. Alternatively, a slight 
increase in membrane-bound IL2Rα upon replicative 
senescence may reflect the activation state or ability to 
trans-present IL2Rα rather than responsiveness to IL-
2, similar to what was previously reported for myeloid 
dendritic cells [58]. In our current study, we cannot 
discriminate between these events. In addition, our data 
also point out to the interesting phenomenon, that the 
production of IL2Rα drastically declines on transcriptional 
level with replicative senescence of adipose-derived 
MSCs. In accord with a previous report that in addition 
to cell surface IL-2Rα, IL-2Rα can exist in a soluble 
form (sIL-2Rα), which could be released from the cell 
surface [59], we speculate that our data might provide an 
indication of a less available soluble form of IL2Rα upon 
replicative aging of hADSCs. 
In our current study, we also attempted to interrogate 
biochemical gene signaling networks activated in IL-2 
primed SR and SEN hADSCs in order to gain insights into 
impact of the replicative senescence on adipose-derived 
MSCs function. Differential gene expression analysis, 
comparing IL-2 treated versus untreated SR and SEN cells, 
allowed us to uncover a number of individual genes that 
are up- or down-regulated upon IL-2 stimulation. However, 
the biological response to IL-2 treatment of hADSCs is 
not likely to be orchestrated by individual genes acting 
alone. Rather, this response is more likely to be based 
on multiple co-regulated genes that function together in 
integrated pathways. Furthermore, the biological pathways 
that are affected by IL-2 treatment are also likely to be 
functionally interconnected in the sense that they work 
together to execute cellular responses to stimulation by IL-
2. We analyzed genes designated as up- or down-regulated 
in IL-2 treated SR and SEN hADSCs using an integrated 
gene-set enrichment and pathway network approach in an 
attempt to capture the biological reality of coordinated 
cellular responses to IL-2 stimulation. To do this, we first 
identified pathways that were statistically enriched for 
up- or down-regulated genes, and then we related these 
pathways based on the differentially expressed genes 
that they have in common (Table 1 and Table 2). We also 
weighted the pathway network representation based on the 
numbers of differentially expressed genes in each pathway 
and the extent to which different pathways share sets of 
differentially expressed genes. This approach allowed 
us to elucidate a highly connected network structure 
with numerous functionally related pathways as well as 
functionally relevant network substructures.
Notably, upon senescence of hADSCs IL-2 is less 
stimulatory for the gene pathways promoting proliferation 
(cell cycle pathway, q-value = 1.54 e-5), imposing 
G2 checkpoint (G2 pathway, q-value = 5.94e-4), p53 
pathway (q-value = 1.18e-2), major signal transduction 
MAPK pathway (MAPK, q-value = 2.42e-4) and its 
major subgroup ERK pathway (ERK, q-value = 2.62e-
2), which regulate important cellular function such as 
survival, migration and proliferation [60]. Our analysis 
further corroborates the previous finding that PDGF-
induced AKT and ERK pathways regulate opposing fate 
decisions of proliferation and differentiation in order to 
promote MSC self-renewal [61]. Activation of the genes 
representing these pathways was observed only after 
ex-vivo IL-2 priming of actively self-renewing human 
ADSCs but not their senescent counterparts (Table 
1, left side). Apparently, a different arm of the AKT 
pathway (including up-regulated FOXO1, FOXO3 and 
FOXO4 genes) acts upon exposure of SEN hADSCs to 
inflammatory environment (Table 1, right side), which 
could potentially be tumorigenic. The AKT pathway may 
be important to promote IL-6 secretion (both the gene and 
its biological pathway targets are transcriptionally up-
regulated in senescence Table1 and Figure 5B), which in 
turn has been shown to contribute to the establishment of 
the inflammatory environment and promote the resistance 
of fibroblasts to apoptosis [62-64].
Our data also provide insights into the functionality 
of MSCs in carcinogenic settings. Both SR and SEN 
hADSCs primed by IL-2 are marked by drastic increases in 
expression of transforming growth factors alpha and beta 
(TGFα, TGFβ1 and TGFβ2), transforming growth factor 
beta receptor TGFBR2 and transforming growth factor 
beta receptor-associated protein TGFBRAP1, as well as 
transforming growth factor beta-induced (TGFBI) genes 
(Figure 5A). Secreted TGFβ is believed to be important 
in regulation of the immune system by promoting 
differentiation of CD4+ T-cells and inhibiting immune-
surveillance, thereby imposing immunosuppression [65]. 
However, the higher level of TGFβ expression in hADSCs 
after exposure to IL-2 might promote carcinogenesis. 
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Since parts of the TGFβ signaling pathway are shown to 
be mutated in cancer cells (see for the details in [66]), this 
allows cancer cells to escape TGFβ-induced cell cycle 
block, differentiation or apoptosis, while the surrounding 
stromal, immune, endothelial and smooth muscle cells 
still read the TGFβ signaling as a potent suppressor 
of proliferation and trigger of differentiation causing 
immunosuppression and angiogenesis in the cancer cell 
microenvironment. Cancer cells exploit this environmental 
condition to their advantage. In the absence of the 
effector T-cells, which normally attack cancer, cancer 
cells become more invasive [66-68]. Based on these 
observations, we speculate that therapeutic delivery of 
MSCs subjected either to prolonged expansion in culture, 
or into the patients burdened by chronic inflammation, 
are likely to create a microenvironment conducive to 
cancer progression and metastasis. Similarly, systemic 
administration of IL-2 as the treatment for cancer [69,70] 
should take into consideration the age of the patient, since 
aging might diminish MSCs similar to what is seen for 
their ex-vivo replicative aging.
In support of this hypothesis, in IL-2 treated SEN 
hADSCs prominent up-regulated genes are enriched for 
pathways associated with inflammation (IL-6 pathway, 
q-value = 5.55e-3) and EGF signaling (q-value = 2.33e-
4) that have been proven to provide a survival advantages 
to mesenchymal stem cells [71]. The SEN hADSCs 
primed with IL-2 are also marked by increased expression 
of IL-1β, IL-6 and IL-12 (Figure 5B), cytokines known 
to stimulate IL-17 from lymphocytes [72-74]. Our 
data also indicate that lymphocytes are the only source 
of IL-17D production, and those mesenchymal stem 
cells, particularly upon their senescence, display high 
transcriptional activity of IL-17 when subjected to a pro-
inflammatory environment (Figure 5A). We hypothesize 
that the MCS-derived IL-17D together with MCS-derived 
CSF-1 might induce systemic neutrophil expansion and 
macrophages infiltration similar to studies indicating 
a critical role for these factors in promoting cancer 
progression and metastasis [75-77] as well as in a number 
of inflammatory diseases including psoriasis [73]. 
The observed connection to the angiogenic VEGF 
pathway (q-value = 5.24e-3) (Table 1, right side and 
Figure 5D) and the enhanced capacity of SEN hADSCs to 
migration (Figure 1C, 1D) may suggest that IL-2 primed 
SEN mesenchymal stem cells could acquire properties 
necessary to support a tumorigenic environment and 
metastasis. In addition, up-regulation of the genes included 
in nitric oxide synthase pathway (iNOS) NOS1 pathway 
(q-value = 8.32e-2) in hADSC upon replicative senescence 
once again support the hypothesis that mesenchymal stem 
cells undergoing senescence can acquire metastasis-
promoting properties via immunosuppression.
In the current study, we further corroborated that 
aging poses a significant threat to adult MSC function 
[78-80] [7] by providing evidence that critical pathways 
essential for support of proliferation and DNA repair are 
down-regulated in hADCSs upon senescence: Cell Cycle 
pathway (q-value = 2.52e-5), MCM pathway (q-value = 
1.62e-8), RB pathway (q-value = 6.97e-5) ATM pathway 
(q-value = 3.28e-2), p53 pathway (q-value = 1.86 e-2) 
shown in Table 2. Overall, our data indicate that there 
are more biological pathways subjected to IL-2 triggered 
down-regulation in senescence then in self-renewal and 
these biological pathways are interconnected (Table 2), 
further linking together a physiological impairment of 
IL-2 response upon replicative aging of hADSCs, thus 
suggesting that such impairment might be an integral to 
adipose-derived stem cell deviated function in vivo and 
upon clinical applications. 
Our results, in concert with previously published 
data, should raise awareness that replicative aging 
of adult adipose-derived stem cells can impair their 
immunomodulatory, angiogenic and antioxidative 
functions, and in part, can explain several contradicting 
studies related to either tumor-promoting [81-83] or 
tumor-suppressive properties [55,84] of adipose-derived 
MSCs. Our data also help to define biological pathways 
and gene targets for in depth exploration of functional 
activities of adipose-derived MSC therapeutic approaches 
and further refinement of their application in clinical 
settings.
MATERIALS AND METHODS
Isolation, culture and characterization of MSCs
MSCs used in this research were isolated from 
human adipose tissues obtained from healthy adult female 
donors age 32 and 45 undergoing routine liposuction 
procedures at the UCSD medical center, San Diego, CA. 
The MSC isolation protocol was approved by the local 
ethics committee and performed as previously described 
[7]. Isolated adipose-derived stem cell lines were grown in 
DMEM/F12 medium (Life Technologies). In accordance 
with the MSC minimal definition criteria set by the 
International Society for Cellular Therapy [85], flow 
cytometric analysis showed that hADSCs express CD29, 
CD73, CD90 and CD105 but do not express CD11b, 
CD14, CD19, CD34, CD45, CD80, CD86 (antibodies 
from eBiosciense, USA). Morphological analysis showed 
that the cells present a fibroblast-like morphology, were 
plastic adherent and capable of adipogenic, chondrogenic 
and osteogenic differentiation under in vitro conditions 
using commercially available differentiation mediums 
(Invitrogen, USA). Cumulative population doublings 
(PD) were calculated as PD = log(N/N0) x 3.33 across 
the multiple passages as a function of the number of days 
of growth in culture as described in [7], where N0 is the 
number of cells plated in the flask and N is the number 
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of cells harvested at this passage. hADSCs PD 4 or PD 6 
for self-renewing populations (SR) and PD 41 and 38 for 
senescent populations (SEN) were used in all experiments. 
Treatment with recombinant IL-2 (Peprotech, USA) was 
performed as described in [86]. 20U/ml of IL-2 was added 
to the culturing media for 24 hours at 37oC. 
Senescence–associated SA-β galactosidase assay
The assay for monitoring the expression of pH-
dependent senescence-associated β-galactosidase activity 
(SA-βGal) was performed as described in manufacturer’s 
kit (BioVision) and previously published in [7]. The 
cultured hADSCs were fixed with fixative solution for 
15 minutes at room temperature, washed with twice 
with PBS and stained with X-Gal containing supplement 
overnight at 37°C. The cells were washed twice with PBS, 
and the images were captured using a microscope (Nikons, 
TE300, DXM1200 Digital Camera, Japan).
Migration and invasion assay
Transwell filters were from Corning Incorporated 
(Acton, MA, USA) and all the cytokines in use were 
obtained from Peprotech Inc. (Rocky Hill, NJ, USA). 
The migration assay was performed as described in [27] 
using 8mm thick Transwell chambers. For the Transwell 
migration assay, 1.0 x 104 cells were suspended in 80μl 
of serum-free α-MEM and seeded in the upper chamber 
of 24-well Transwell plates containing 8 mm pore size 
filters (Corning, Costar, USA). In the lower chamber, 600 
μl of DMEM or medium containing cytokines: IL-2, IL-
6, IL-8, TNF-α, HMGβ1 was added. The concentrations 
used were: 50ng/ml IL-2, IL-6, IL-8 and HMGβ1; 30ng/
ml TNF-α as described in [27]. hADSCs were incubated 
at 37°C for 16h. The cells retained in the upper chamber 
were removed by swab and those that had migrated 
through the filter were fixed with 4% paraformaldehyde 
for 20 minutes at room temperature and stained overnight 
with 5% toluidine blue. The cells were counted at the 
lower side; in five different randomly selected 10x fields 
using a bright-field microscope (NikonTE300, DXM1200 
Digital Camera, Japan). These experiments were done 
with hADSCs of two female donors age 32 and 45, either 
self-renewing (SR) or senescent (SEN) populations, with 
each donor sampled more than three times.
Enzyme-linked immunosorbent assays (ELISA)
hADSCs (SR or SEN) were plated at a density of 
105 cells per 10 cm2 dish and treated with 20 U/mL of 
IL-2 for 24 hour, with untreated controls as previously 
described in [86]. Then, cell membrane-associated protein 
fractions were prepared using Mem-PER Plus #89842 
(ThermoFisher Scientific) following the manufacturer’s 
protocol. Measurements of the concentrations of IL-2 
receptors alpha and beta were obtained using human 
IL-2R alpha and human IL-2R beta ELISA kits #ELH-
IL2Ra and #ELH-IL2Rb (RayBiotech, Inc) respectively. 
The optical densities for the standards (recombinant IL-2 
receptors alpha and beta) as well as the experimental 
samples were measured at 450 nm by SPECTRA Max Plus 
(Molecular Devices) and concentrations were calculated 
as described in the manufacturer’s protocol.
Real-time quantitative polymerase chain reaction
Total RNA was isolated from hADSCs using the 
RNeasy Mini Kit (Qiagen, Germany). cDNA was then 
synthesized using the RevertAid First Strand cDNA 
Synthesis Kit (Fermentas, USA). Real-time quantitative 
polymerase chain reaction (qPCR) was performed using 
TaqMan instrument. The expression levels were calculated 
as 2− ∆∆Ct, where relative expression was determined by 
normalization to beta-actin gene expression. All assays 
were conducted in triplicates and negative control samples 
without cDNA were used. 
IL-2 Receptor Alpha chain (IL2Rα) For: 5’- 
CTGCCACTCGGAACACAAC-3’ and Rev: 5’- 
TGGTCCACTGGCTGCATT-3’. 
IL-2 Receptor Beta chain (IL2Rβ) For: 5’- 
ACTCGAGAGCCAACATCTCC-3’ and Rev: 5’- 
TCCGAGGATCAGGTTGCAG-3’. 
IL-2 Receptor Gamma 1 chain (IL2Rγ1) For: 
5’- TGGATGGGCAGAAACGCTA-3’ and Rev: 5’- 
GGCTTCCAATGCAAACAGGA-3’. 
STAT 5A For: 5’- ACGCAGGACACAGAGAATGA 
-3’ 
and Rev: 5’- CTGGGCAAACTGAGCTTGG-3’. 
STAT 5B For: 5’- ACACAGCTCCAGAACACGT 
-3’ and
 Rev: 5’- TGTTGGCTTCTCGGACCAA-3’. 
VEGF A For: 5’- GGAGGAGGGCAGAATCATCA 
-3’ and 
Rev: 5’- ATCAGGGGCACACAGGATG-3’. 
Transcriptomic analysis
Transcriptomic analysis was performed with 
IL-2 treated and untreated (control group) SR and SEN 
hADSCs as previously described in [86]. The two 
genotypes shown in Figure 1A were used for the analysis 
of four different conditions: self-renewal (SR), replicative 
senescence (SEN) without or with IL-2 stimulation 
respectively.  Cells were seeded in DMEMF12 (106) 
media for each experimental condition, and IL-2 treatment 
was performed by adding 20U/ml of recombinant IL-2 
(Peprotech, USA) directly into the media for 24 hours 
as previously described in [86]. Total RNA was isolated 
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from samples using TRIzol reagent (Invitrogen, USA) 
according to the manufacturer’s instructions. Samples 
from two different patients were combined together for 
the relevant conditions and RNA concentrations were 
measured with the Qubit 2.0 fluorometer using the RNA 
HS Assay kit (Invitrogen, Life technologies, USA).
100ng of total RNA from each sample was used to 
construct the libraries for sequencing on the Ion ProtonTM 
System (Life technologies, USA) following manufacturers 
instructions. Prior to rRNA depletion and RNA-seq 
library construction, the ERCC RNA Spike-In Control 
mix (Ambion, Life Technologies) was added to total RNA 
for quality control analysis. The ERCC RNA Spike-In 
control mix contains 92 transcripts 250-2000 nt in length 
that mimic natural eukaryotic mRNAs. According to the 
protocol provided by manufacturer, for 100 ng of total 
RNA was added to 2ul of Mix1 in dilution 1:1000 of 
spike-in. Afterwards, rRNA depletion was performed with 
the Low Input Ribominus Eukaryote System v2 (Ambion, 
Life technologies, USA). cDNA libraries were constructed 
with Ion total RNA-seq kit v2 (Ambion, Life technologies, 
USA), and barcoded with Ion Xpress RNA-seq barcode 
(Ambion, Life technologies). The size distribution and 
quantification of the libraries were performed on a 
Bioanalyzer 2100 (Agilent technologies, USA). Library 
sequencing was performed on the Ion ProtonTM System 
with P1 chip, and each library was sequenced 3 times.
RNA-seq data analysis
RNA-seq reads from individual Ion ProtonTM 
System sequencing runs were combined for each of 
the four libraries. Sequence reads were mapped to the 
reference human genome assembly hg19 (GRCh37) 
using the Torrent Mapping Alignment Program (TMAP, 
Life technologies). The quality of the four condition-
specific combined RNA-seq runs was evaluated by 
comparing the expected counts of ERCC spike-in RNA 
sequences, obtained from the manufacturer’s website, 
against the observed counts of RNA-seq tags that map 
to the same sequences (Supplementary Figure 2). Initial 
gene expression levels were taken as the sum of exon-
mapped reads for individual NCBI RefSeq gene models 
(c), and lowly expressed genes (read counts per million 
< 1) were removed from subsequent analyses. For each 
library, individual gene expression levels were normalized 
using the beta-actin (ACTB) expression levels (cACTB) 
and the total exon length l of each gene. For library j, 
the beta-acting normalization factor sj was calculated 
as , and the final normalized 
expression value for gene i in library j was calculated as
. Differential gene expression analysis 
between pairs of libraries was performed using the 
program GFOLD v1.1.3 [87]. GFOLD was chosen based 
on its demonstrated superior performance in characterizing 
differentially expressed genes in the absence of replicate 
data sets. GFOLD analysis yields a score that measures the 
extent of differential gene expression between conditions; 
the recommended GFOLD score cut-off of ±0.01 was used 
to define differentially expressed genes here. Functional 
enrichment analysis for differentially expressed genes 
between pairs of libraries was performed using the 
program GSEA v2.1.0 [88]. Specifically, individual 
pathways containing multiple genes that are up-regulated 
or down-regulated upon IL-2 treatment in SR, SEN or 
both were identified using GSEA. Individual pathways 
for specific sets of differentially regulated genes (IL-2+ 
up-regulated in SR and/or SEN and IL-2+ down-regulated 
in SR and/or SEN) were related using networks where the 
nodes correspond to pathways and the edges correspond to 
the presence of shared genes between pathways. 
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